ArticleCurrent oncology (Toronto, Ont.)2023

Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's Perspective.

Fatemeh Mirzayeh Fashami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.